Efficacy and Safety of Ripretinib vs. Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor Previously Treated with Imatinib: A Phase 2, Multicenter, Randomized, Open-Label Study in China

A bridging study of INTRIGUE study to assess the efficacy and safety of ripretinib versus sunitinib as second-line treatment in Chinese GIST patients.

Source: European Journal of Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Jian Li, Jun Zhang, Yanqiao Zhang, Haibo Qiu, Yanbing Zhou, Yongjian Zhou, Xinhua Zhang, Ye Zhou, Yuping Zhu, Yong Li, Ming Wang, Kuntang Shen, Kaixiong Tao, Xin Wu, Haijiang Wang, Bo Zhang, Jiayu Ling, Yingjiang Ye, Xingye Wu, Hongyan Qu, Yue Ma, Xuelong Tags: Original Research Source Type: research